EyePoint Pharmaceuticals Inc (EYPT)
NASDAQ:EYPT
Top Page
EyePoint Pharmaceuticals
(NASDAQ:EYPT)
Select Model
Select Model
Rating:52Neutral
Price Target:
$14.50
▲(1.12% Upside)
Action:ReiteratedDate:04/14/26
The score is held back primarily by weak financial performance (widening losses, steep cash burn, and declining/lumpy revenue) and limited valuation support (negative P/E, no dividend yield). Offsetting these risks are a comparatively solid capital structure and a more favorable earnings-call backdrop driven by defined Phase 3 milestones, reported clean safety to date, and stated runway into 2027, while technical indicators remain mixed.
Positive Factors
Differentiated multi-mechanistic therapy and Phase 2 efficacy
Duravuy's multi-mechanistic inhibition (VEGF, PDGF, IL-6 via JAK1) plus Phase 2 signals of earlier and durable vision benefit indicate a structural product advantage. If Phase 3 confirms these effects, the mechanism and efficacy profile support long-term differentiated market positioning versus single-mechanism anti-VEGFs.
Negative Factors
High cash burn and negative free cash flow
Very large negative operating and free cash flows reflect intensive Phase 3 spend and ongoing R&D, creating structural funding needs. Sustained cash burn increases reliance on external financing, which can dilute shareholders and constrain strategic flexibility over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Differentiated multi-mechanistic therapy and Phase 2 efficacy
Duravuy's multi-mechanistic inhibition (VEGF, PDGF, IL-6 via JAK1) plus Phase 2 signals of earlier and durable vision benefit indicate a structural product advantage. If Phase 3 confirms these effects, the mechanism and efficacy profile support long-term differentiated market positioning versus single-mechanism anti-VEGFs.
Read all positive factors
EyePoint Pharmaceuticals (EYPT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.21B
Dividend YieldN/A
Average Volume (3M)1.14M
Price to Earnings (P/E)―
Beta (1Y)1.81
Revenue Growth-7.38%
EPS Growth-49.03%
CountryUS
Employees165
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.81
Shares Outstanding83,431,950
10 Day Avg. Volume937,562
30 Day Avg. Volume1,138,283
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)4.37
Price to Sales (P/S)42.66
P/FCF Ratio-5.50
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue36.32
Enterprise Value/Gross Profit38.88
Enterprise Value/Ebitda-4.76
Forecast
1Y Price Target
$36.60Price Target Upside155.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-3.21
Revenue Forecast (FY)$3.78M
EyePoint Pharmaceuticals Business Overview & Revenue Model
Company Description
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-...
How the Company Makes Money
EyePoint makes money primarily by commercializing ophthalmic products and by generating revenue from collaborations related to its drug delivery and product development activities. Product revenue is driven by sales of its marketed ophthalmic ther...
EyePoint Pharmaceuticals Key Performance Indicators (KPIs)
Any
Revenue Breakdown
Analyzes the sources of the company's revenue, highlighting key products or services that drive sales and indicating areas of growth or dependency.
Analyzes the sources of the company's revenue, highlighting key products or services that drive sales and indicating areas of growth or dependency.
Data provided by:
The Fly
The FlyEyePoint Pharmaceuticals Earnings Call Summary
Earnings Call Date:Mar 04, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 06, 2026
Earnings Call Sentiment Positive
The call presents a constructive clinical and commercial story centered on rapid Phase 3 progress (wet AMD readouts mid-2026, DME pivotal dosing underway), a differentiated multi-mechanistic asset with promising Phase 2 efficacy and a clean safety profile in ~190 patients, along with manufacturing and commercial hires to support a potential launch. Offsetting these positives are material financial headwinds from sharply lower quarter and year revenues, substantially higher operating expenses and an increased net loss, with cash down year-over-year though raised financing provides runway into 2027. Regulatory/commercial execution and continued safety monitoring remain key near-term risks. Overall, the positive clinical momentum and adequate near-term funding tip the balance toward a favorable outlook despite clear financial burn and execution risks.Positive Updates
Advancing DuraVu into Phase 3 across key indications
Pivotal programs progressing: two Phase 3 wet AMD trials (Lugano and LUCIA) ongoing with top-line data expected beginning mid-2026; first patients dosed last week in both pivotal Phase 3 DME trials (COMO and CAPRI) with top-line DME data anticipated in 2027.
Negative Updates
Sharp quarter-over-quarter revenue decline
Q4 net revenue of $0.6 million vs $11.6 million in Q4 2024, a decrease of approximately 95%, driven primarily by recognition of remaining deferred revenue tied to the YUTIQ license agreement.
Read all updates
Q4-2025 Updates
Positive
Negative
Advancing DuraVu into Phase 3 across key indications
Pivotal programs progressing: two Phase 3 wet AMD trials (Lugano and LUCIA) ongoing with top-line data expected beginning mid-2026; first patients dosed last week in both pivotal Phase 3 DME trials (COMO and CAPRI) with top-line DME data anticipated in 2027.
Read all positive updates
Company Guidance
EyePoint’s guidance and milestones were detailed and metric‑rich: top‑line Phase 3 wet AMD data from Lugano (with LUCIA closely following) is expected beginning mid‑2026 (next DMC safety review in May), and two pivotal DME Phase 3 trials (COMO and CAPRI) have begun randomization with first patients dosed last week, enrollment expected to complete in 2026 and top‑line DME data anticipated in 2027; cash and investments totaled $306M at 12/31/2025 (down from $371M a year earlier) after a $173M follow‑on in October, and management expects this to fund operations into 2027 and fully fund the DME program and NDA preparation for wet AMD; Q4 2025 revenue was $0.6M (Q4 2024: $11.6M) and FY revenue $31M (2024: $43M); Q4 OpEx $71M (vs $57M), FY OpEx $275M (vs $189M); Q4 net loss ~ $68M, $0.81/sh (vs $41M, $0.64), FY net loss $232M, $3.17/sh (vs $131M, $2.32); net non‑operating income was $3M in Q4 and $12M for the year; clinical metrics include >190 patients treated across four completed trials with no drug‑attributed ocular/systemic SAEs, cataracts of 5.8% in the 191‑patient database (DAVIO‑2 arms ~8%, aflibercept ~9%), floaters 5.2%, DAVIO‑2 unsupplemented treated eyes gained ~2.1 letters vs control, VERONA showed ~4–5 letter early separation and ~40 µm CST benefit at week 4, insert payload ~94% drug/6% matrix, vorolanib JAK1 IC50 ≈80 nM, ~140 global sites planned across the DME studies, Phase 3 dosing uses two inserts with an expected first‑year injection burden of two DuraVu vs five aflibercept (a theoretical 60% reduction if no supplementation; ~40% reduction using DAVIO‑2 supplementation rates), and a 41,000 sq ft cGMP facility with ~60 FTEs is online supporting CMC and commercial supply.EyePoint Pharmaceuticals Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
72
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 31.37M | 43.27M | 46.02M | 41.40M | 36.94M |
| Gross Profit | 29.30M | 39.56M | 41.39M | 33.08M | 28.76M |
| EBITDA | -243.43M | -129.23M | -69.00M | -96.62M | -50.15M |
| Net Income | -231.96M | -130.87M | -70.80M | -102.25M | -58.42M |
Balance Sheet | |||||
| Total Assets | 364.00M | 418.46M | 355.18M | 180.36M | 263.37M |
| Cash, Cash Equivalents and Short-Term Investments | 306.09M | 370.91M | 331.05M | 144.56M | 211.56M |
| Total Debt | 20.77M | 21.86M | 4.91M | 46.35M | 39.20M |
| Total Liabilities | 57.88M | 81.96M | 88.86M | 83.99M | 78.99M |
| Stockholders Equity | 306.11M | 336.50M | 266.32M | 96.37M | 184.38M |
Cash Flow | |||||
| Free Cash Flow | -243.39M | -130.28M | -1.61M | -67.16M | -50.25M |
| Operating Cash Flow | -240.11M | -126.23M | 1.88M | -65.00M | -50.10M |
| Investing Cash Flow | 68.58M | -219.35M | -3.31M | -17.27M | -33.12M |
| Financing Cash Flow | 173.65M | 164.02M | 187.07M | -690.00K | 216.90M |
EyePoint Pharmaceuticals Technical Analysis
Positive
14.34
Price Trends
14.37
Negative
15.24
Negative
13.50
Positive
Market Momentum
-0.11
Negative
53.64
Neutral
85.16
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EYPT, the sentiment is Positive. The current price of 14.34 is above the 20-day moving average (MA) of 13.39, below the 50-day MA of 14.37, and above the 200-day MA of 13.50, indicating a neutral trend. The MACD of -0.11 indicates Negative momentum. The RSI at 53.64 is Neutral, neither overbought nor oversold. The STOCH value of 85.16 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for EYPT.
EyePoint Pharmaceuticals Risk Analysis
EyePoint Pharmaceuticals disclosed 55 risk factors in its most recent earnings report. EyePoint Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
EyePoint Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $2.07B | ― | -2.05% | ― | 1128.17% | ― | |
56 Neutral | $1.21B | 440.78 | 1.15% | ― | 26.54% | ― | |
55 Neutral | $3.08B | -10.13 | -50.30% | ― | 53.28% | 21.77% | |
54 Neutral | $784.33M | 10.69 | -1065.47% | ― | 96.83% | -61.92% | |
52 Neutral | $1.21B | -5.61 | -88.31% | ― | -7.38% | -49.03% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $987.28M | ― | 170.21% | ― | 8.00% | -10.15% |
* Healthcare Sector Average
EYPT
EyePoint Pharmaceuticals
14.63
9.08
163.60%
URGN
Urogen Pharma
21.51
11.12
107.03%
MGTX
Meiragtx Holdings
11.25
5.93
111.47%
STOK
Stoke Therapeutics
35.54
27.98
370.11%
TNGX
Tango Therapeutics
25.33
24.05
1878.91%
PHAR
Pharming Group
17.80
9.71
120.02%
EyePoint Pharmaceuticals Corporate Events
Business Operations and StrategyProduct-Related Announcements
EyePoint Highlights DURAVYU Phase 3 Progress and Cash Runway
Positive
Apr 13, 2026
On April 13, 2026, EyePoint, Inc. posted an updated investor presentation outlining progress on DURAVYU, an investigational vorolanib intravitreal insert now in Phase 3 trials for wet AMD and DME. The company highlighted that its pivotal wet AMD t...
Business Operations and StrategyLegal Proceedings
EyePoint Sues Ocular Therapeutix Over Alleged Defamation
Negative
Mar 20, 2026
On March 20, 2026, EyePoint, Inc. filed a lawsuit in Middlesex County Superior Court in Massachusetts against Ocular Therapeutix, Inc., alleging the rival disseminated false or misleading statements about EyePoint and the clinical results of its l...
Business Operations and StrategyProduct-Related Announcements
EyePoint Starts Global Phase 3 Trials for DURAVYU
Positive
Mar 2, 2026
On March 2, 2026, EyePoint announced that the first patients have been dosed in its global Phase 3 COMO and CAPRI clinical trials evaluating DURAVYU for diabetic macular edema, signaling the start of pivotal late-stage testing in a major retinal i...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.